About
Co-Founder of Resverlogix Corp. (TSX:RVX), and Chief Scientific Officer since 2003.
Currently Professor of Medicine and Biochemistry & Molecular Biology and Director of the Libin Gene / Cell Therapy Unit within the Faculty of Medicine at the University of Calgary.
Specializes in the areas of Endocrinology, Internal Medicine, Molecular Biology and Gene/Cell Therapy.
Author &/or co-author of over 275 articles and abstracts and invited to sit on more than 40 national or international panels / committees.
Consulted for leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.
Education
–